Ahead Of The Mix: Symphogen Leads The Way To Antibody Combinations
This article was originally published in Start Up
Executive Summary
The concept of multiple antibodies in one mixture to treat disease, once solely the provenance of serum-derived polyclonal therapies, is enticing a new wave of developers. With a technological head start and a vault full of private backing, Danish firm Symphogen is the field’s pioneer – and hopes to avoid the arrows.